George Barth Geller Distinguished Professor of Immunology, Duke University
Appears in 1 story
Leading ongoing HER2 vaccine clinical trials
Metastatic breast cancer typically kills most patients within five years. A small group of women vaccinated in a Duke University clinical trial two decades ago have defied that prognosis entirely; all remain alive today. Researchers found these survivors still carry specialized immune cells that recognize their cancer, offering a model for why some therapeutic vaccines produce lasting results.
Updated Jul 9
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
